Supplementary Online Content


**eFigure 1.** Relationship between relative risk for the endpoints of microalbuminuria, macroalbuminuria, doubling of serum creatinine, and end-stage renal disease

**eFigure 2.** Risk of bias graph

**eFigure 3.** Risk of bias summary

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1 - Relationship between relative risk for the endpoints of microalbuminuria, macroalbuminuria, doubling of creatinine and ESRD by A. Median Year of Enrollment, B. Years Since Diabetes Diagnosis, C. Duration of therapy in the trial, D. Difference in HbA1C between intervention and control groups, E. Median achieved HbA1C in the intervention arms.
A. Median Year of Enrollment vs. Risk for Microalbuminuria

- UKPDS34
- ADVANCE
- ACCORD
- VA Feasibility Trial

\[ y = 0.002x - 4.086 \]
\[ R^2 = 0.005 \]
\[ P=0.43 \]

B. Median Year of Enrollment vs. Risk for Macroalbuminuria

- UKPDS33
- ADVANCE
- ACCORD
- VADT

\[ y = 0.005x - 10.59 \]
\[ R^2 = 0.022 \]
\[ P=0.31 \]

C. Median Year of Enrollment vs. Risk for Doubling of Creatinine

- UKPDS33
- ADVANCE
- VADT

\[ y = 0.035x - 69.63 \]
\[ R^2 = 0.983 \]
\[ P=0.02 \]

D. Median Year of Enrollment vs. Risk for ESRD

- UKPDS34
- ACCORD
- VADT

\[ y = -0.012x + 24.97 \]
\[ R^2 = 0.277 \]
\[ P=0.39 \]
B. Years Since Diabetes Diagnosis vs. Risk for Microalbuminuria

- ACCORD
- ADVANCE
- VADT
- Kumamoto VA Feasibility Trial

- \[ y = -0.022x + 0.880 \]
- \[ R^2 = 0.146 \]
- \[ P = 0.40 \]

Years Since Diabetes Diagnosis vs. Risk for Macroalbuminuria

- ACCORD
- ADVANCE
- VADT
- Kumamoto

- \[ y = -0.028x + 0.791 \]
- \[ R^2 = 0.152 \]
- \[ P = 0.44 \]

Years Since Diabetes Diagnosis vs. Risk for Doubling of Creatinine

- ACCORD
- ADVANCE
- VADT
- UKPDS33

- \[ y = 0.056x + 0.480 \]
- \[ R^2 = 0.811 \]
- \[ P = 0.08 \]

Years Since Diabetes Diagnosis vs. Risk for ESRD

- ACCORD
- VADT
- UKPDS33

- \[ y = -0.027x + 0.932 \]
- \[ R^2 = 0.233 \]
- \[ P = 0.35 \]
### C. Duration of Therapy vs. Risk for Microalbuminuria

- **ACCORD**
- **ADVANCE**
- **UKPDS33**
- **UKPDS34**
- **VADT**
- **Kumamoto**

Relative Risk vs. Duration of Therapy (years)

- $y = 0.047x + 0.436$
- $R^2 = 0.342$
- $P=0.17$

**Duration of Therapy vs. Risk for Microalbuminuria**

### Duration of Therapy vs. Risk for Macroalbuminuria

- **ACCORD**
- **ADVANCE**
- **UKPDS33**
- **VADT**
- **Kumamoto**

Relative Risk vs. Duration of Therapy (years)

- $y = 0.041x + 0.344$
- $R^2 = 0.184$
- $P=0.39$

**Duration of Therapy vs. Risk for Macroalbuminuria**

### Duration of Therapy vs. Risk for Doubling of Creatinine

- **ACCORD**
- **ADVANCE**
- **VADT**
- **UKPDS33**

Relative Risk vs. Duration of Therapy (years)

- $y = -0.096x + 1.513$
- $R^2 = 0.963$
- $P=0.018$

**Duration of Therapy vs. Risk for Doubling of Creatinine**

### Duration of Therapy vs. Risk for ESRD

- **ACCORD**
- **ADVANCE**
- **UKPDS33**

Relative Risk vs. Duration of Therapy (years)

- $y = 0.041x + 0.471$
- $R^2 = 0.207$
- $P=0.38$

**Duration of Therapy vs. Risk for ESRD**
eFigure 2. Risk of Bias Graph

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other bias

Legend:
- Green: Low risk of bias
- Yellow: Unclear risk of bias
- Red: High risk of bias
## eFigure 3. Risk of Bias Summary

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCORD</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>ADVANCE</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Kurnamoto</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>UKPDS 33</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>UKPDS 34</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>VADT</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>VADT Feasibility Trial</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

© 2012 American Medical Association. All rights reserved.